Prescribed Medication Approved for IBS-D1*
Image of the small and large intestines with a microscopic look at the inside of a segment of the intestines explaining that microbial imbalance has been linked to symptoms of irritable bowel syndrome with diarrhea.

HOW XIFAXAN WORKS

XIFAXAN is the only FDA-approved treatment that alters the microbiota in IBS-D.2-4 Microbial imbalance has been linked to symptoms of IBS-D.3,5,6 Evidence suggests that XIFAXAN works primarily in the gut by inhibiting protein synthesis in bacteria linked to IBS-D symptoms.2-4

Learn More
Proven Symtom Relief

PROVEN SYMPTOM RELIEF

XIFAXAN provided significant relief of both abdominal pain and diarrhea2,3‖

See XIFAXAN Efficacy Data
Map of the USA depicting the statement that 98% of insured patients have coverage for XIFAXAN medication if prescribed.

ACCESS TO XIFAXAN

98% of commercially insured patients have coverage for XIFAXAN1

See XIFAXAN Coverage

XIFAXAN RESOURCES

Download resources for your practice

Learn More

Sign up to get useful information regarding XIFAXAN.

References: 1. Data on file. Salix Pharmaceuticals. Bridgewater, NJ. 2. XIFAXAN [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 3. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. 4. Rivkin A, Rybalov S. Update on the management of diarrhea-predominant irritable bowel syndrome: focus on rifaximin and eluxadoline. Pharmacotherapy. 2016;36(3):300-316. 5. Ringel Y. The gut microbiome in irritable bowel syndrome and other functional bowel disorders. Gastroenterol Clin North Am. 2017;46(1):91-101. 6. Zhong W, Lu X, Shi H, et al. Distinct microbial populations exist in the mucosa-associated microbiota of diarrhea predominant irritable bowel syndrome and ulcerative colitis. J Clin Gastroenterol. 2017;00:1-13.

INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
  • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
  • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
  • In clinical studies, the most common adverse reactions for XIFAXAN were:
    • HE (≥10%): Peripheral edema (15%), nausea (14%), dizziness (13%), fatigue (12%), and ascites (11%)
    • IBS-D (≥2%): Nausea (3%), ALT increased (2%)
  • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
  • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for full Prescribing Information.

SEE MORE
INDICATIONS

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

IMPORTANT SAFETY INFORMATION
  • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.

You are leaving the XIFAXAN Professional IBS-D website

Thank you for visiting XIFAXAN Professional IBS-D website. By clicking OK, you will be taken to a website or sites where our Privacy Policy and other rules do not apply. Salix Pharmaceuticals does not possess editorial control over the content of the information on such website(s) and therefore does not warrant their accuracy and completeness. You are solely responsible for interactions with such website(s).

OK Cancel
×
x

Thank you for signing up for XIFAXAN resources.